BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22639407)

  • 1. PTEN deletion is rare but often homogeneous in gastric cancer.
    Mina S; Bohn BA; Simon R; Krohn A; Reeh M; Arnold D; Bokemeyer C; Sauter G; Izbicki JR; Marx A; Stahl PR
    J Clin Pathol; 2012 Aug; 65(8):693-8. PubMed ID: 22639407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer.
    Bohn BA; Mina S; Krohn A; Simon R; Kluth M; Harasimowicz S; Quaas A; Bockhorn M; Izbicki JR; Sauter G; Marx A; Stahl PR
    Hum Pathol; 2013 Aug; 44(8):1524-33. PubMed ID: 23465274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 status in unusual histological variants of gastric adenocarcinomas.
    Giuffrè G; Ieni A; Barresi V; Caruso RA; Tuccari G
    J Clin Pathol; 2012 Mar; 65(3):237-41. PubMed ID: 22067088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
    Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
    Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
    Lotan TL; Wei W; Ludkovski O; Morais CL; Guedes LB; Jamaspishvili T; Lopez K; Hawley ST; Feng Z; Fazli L; Hurtado-Coll A; McKenney JK; Simko J; Carroll PR; Gleave M; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Lance R; Troyer D; Squire JA
    Mod Pathol; 2016 Aug; 29(8):904-14. PubMed ID: 27174589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
    Yoshimoto M; Cunha IW; Coudry RA; Fonseca FP; Torres CH; Soares FA; Squire JA
    Br J Cancer; 2007 Sep; 97(5):678-85. PubMed ID: 17700571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
    Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
    World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.
    Saito T; Kondo C; Shitara K; Ito Y; Saito N; Ikehara Y; Yatabe Y; Yamamichi K; Tanaka H; Nakanishi H
    Pathol Int; 2015 Jun; 65(6):309-17. PubMed ID: 25828363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.
    Gonzalez RS; Messing S; Tu X; McMahon LA; Whitney-Miller CL
    Hum Pathol; 2016 Oct; 56():16-21. PubMed ID: 27342907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
    Dai GH; Shi Y; Chen L; Lv YL; Zhong M
    Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.
    Im SA; Lee KE; Nam E; Kim DY; Lee JH; Han HS; Seoh JY; Park HY; Cho MS; Han WS; Lee SN
    Tumori; 2005; 91(6):513-21. PubMed ID: 16457151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
    Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
    J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
    Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
    Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.
    Fusco N; Rocco EG; Del Conte C; Pellegrini C; Bulfamante G; Di Nuovo F; Romagnoli S; Bosari S
    Mod Pathol; 2013 Jun; 26(6):816-24. PubMed ID: 23348899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoexpression of PTEN, HER2/neu, and Ki-67 in endoscopic gastric carcinoma biopsies; their correlation with histological subtypes and one-year survival.
    Acharya S; Thakur B; Mittal R
    Indian J Pathol Microbiol; 2022; 65(1):29-34. PubMed ID: 35074962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.